Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 8/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971825 | 0.84 | PYGL (0.41) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL973186 | 0.84 | PYGL (0.41) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL973508 | 0.83 | GRM5 (0.42) | PYGLGRM5VCPUTS2RALDH1A1 | |
| Hydrochloric Acid SCHEMBL972280 | 0.83 | PYGL (0.41) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL972331 | 0.83 | GRM5 (0.42) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL973076 | 0.82 | PYGL (0.40) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL2348793 | 0.82 | PYGL (0.41) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL971082 | 0.81 | GRM5 (0.41) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL973631 | 0.80 | GRM5 (0.40) | PYGLGRM5VCPUTS2RPTGES | |
| SCHEMBL972196 | 0.80 | GRM5 (0.40) | PYGLGRM5VCPUTS2RPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968963-B1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING ANALGESICS | GRUENENTHAL GMBH (DE) | 2011-10-05 | — | — | EP | claimed |
| US-8008304-B2 | [1] 1-(3-phenyl-propiolyl)-4-(thiophen-3-yl)-piperazine; pain treatments; mGluR5 receptor regulation | Grüenthal GmbH (DE) | 2011-08-30 | — | — | US | claimed |
| US-20080261996-A1 | Substituted propiolic acid amides and their use for producing drugs | GRUNENTHAL GMBH (DE) | 2008-10-23 | — | — | US | claimed |
| EP-1968963-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING ANALGESICS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079959-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING ANALGESICS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| EP-1968963-B1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING ANALGESICS | GRUENENTHAL GMBH (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-8008304-B2 | [1] 1-(3-phenyl-propiolyl)-4-(thiophen-3-yl)-piperazine; pain treatments; mGluR5 receptor regulation | Grüenthal GmbH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-8008304-B2 | [1] 1-(3-phenyl-propiolyl)-4-(thiophen-3-yl)-piperazine; pain treatments; mGluR5 receptor regulation | Grüenthal GmbH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20080261996-A1 | Substituted propiolic acid amides and their use for producing drugs | GRUNENTHAL GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080261996-A1 | Substituted propiolic acid amides and their use for producing drugs | GRUNENTHAL GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1968963-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING ANALGESICS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079959-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING ANALGESICS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261996-A1 | Substituted propiolic acid amides and their use for producing drugs | PPARA, PCCA, PTGES | PYGL 213/4885GRM5 834/4885VCP 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.